A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Mapi Pharma
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2020.
    • 31 Oct 2017 Results presened in a Mapi Pharma Media Release.
    • 31 Oct 2017 According to a Mapi Pharma media release, primary endpoint has been met. (Safety / Adverse events-Number of patients experiencing adverse events and assessments of localized skin reactions at injection sites.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top